Centogene Beheer

Beheer criteriumcontroles 1/4

De CEO Centogene is Kim Stratton, benoemd in Dec2021, heeft een ambtstermijn van 2.92 jaar. De totale jaarlijkse vergoeding van { bedraagt € 2.84M, bestaande uit 24.1% salaris en 75.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.2% van de aandelen van het bedrijf, ter waarde € 36.79K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 7.8 jaar.

Belangrijke informatie

Kim Stratton

Algemeen directeur

€2.8m

Totale compensatie

Percentage CEO-salaris	24.1%
Dienstverband CEO	2.9yrs
Eigendom CEO	1.2%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kim Stratton's beloning veranderd ten opzichte van Centogene's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	€3m	€684k	-€36m
Sep 30 2023	n/a	n/a	-€38m
Jun 30 2023	n/a	n/a	-€40m
Mar 31 2023	n/a	n/a	-€40m
Dec 31 2022	€2m	€861k	-€39m

Compensatie versus markt: De totale vergoeding ($USD 2.96M ) Kim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).

Compensatie versus inkomsten: De vergoeding van Kim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Kim Stratton (62 yo)

2.9yrs

Tenure

€2,843,000

Compensatie

Ms. Kim Stratton serves as Chief Executive Officer at Centogene N.V. since February 18, 2022 and serves as its Member of Management Board and served as its Interim Chief Executive Officer since December 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kim Stratton	CEO & Member of Management Board	2.9yrs	€2.84m	1.2% € 36.8k
Peter Bauer	Interim MD	1.8yrs	€376.00k	0.079% € 2.4k
Jose Miguel Rios	Consultant	less than a year	€1.13m	0.48% € 14.7k
Andrin Oswald	Advisor	2.9yrs	€871.00k	geen gegevens
Ian Rentsch	Chief Commercial Officer & GM of Pharma	1.7yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 39K wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Souêtre	Independent Member of the Supervisory Board	7.8yrs	€20.00k	geen gegevens
Hubert Birner	Independent Member of the Supervisory Board	7.3yrs	€22.00k	geen gegevens
Guido Prehn	Independent Member of the Supervisory Board	7.8yrs	€20.00k	geen gegevens

7.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 39K wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Centogene Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Recent updates

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer

Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD)

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. Announces Changes to Supervisory Board

New major risk - Financial position

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings released: €1.45 loss per share (vs €2.09 loss in FY 2021)

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings released: €0.49 loss per share (vs €0.22 loss in 1Q 2021)

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Executive Officer Richard Stoffelen has left the company

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank

Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank

Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019)

Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study

New 90-day high: €10.55

New 90-day low: €9.06

Third quarter 2020 earnings released: €0.27 loss per share

Centogene N.V. to Report Q3, 2020 Results on Dec 16, 2020

Centogene Expands Express COVID-19 Antigen Testing to Frankfurt Airport

Centogene N.V. Expands Partnership with PTC Therapeutics, Inc. to Generate New Insights for Aromatic L-Amino Acid Decarboxylase Deficiency

Centogene N.V. Announces Partnership with U-Diagnostics B.V. to Provide Increased Covid-19 Testing to Communities Throughout the Netherlands

Centogene's Information Security Management System Awarded Iso/Iec 27001:2017 Accreditation

First half earnings released

New 90-day low: €8.50

Centogene Opens Walk-In COVID-1 Testing Facility At Düsseldorf Airport

Centogene N.V. to Report First Half, 2020 Results on Sep 23, 2020